Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus CADUET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus CADUET.
AFEDITAB CR vs CADUET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis in the liver.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-CoA reductase inhibition) is ~20-30 h.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker + HMG-CoA Reductase Inhibitor